Colorectal Cancer Epidemiology Forecast 2025-2034

Around 10% of all cancer cases are colorectal cancer, making it the second most common cause of cancer-related deaths globally and the third most common type of cancer overall. The World Health Organization (WHO) estimates that by 2040, there will be 3.2 million new colorectal cancer (CRC) cases and 1.6 million deaths worldwide, up from an expected 1.9 million new cases and 935,000 deaths in 2020, with a large percentage of deaths attributable to metastatic disease. The colorectal cancer epidemiology forecast report will provide a comprehensive analysis of the disease's prevalence, incidence trends, and patient demographics across key regions.

Colorectal Cancer Epidemiology Forecast Report Coverage

The “Colorectal Cancer Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of colorectal cancer. It projects the future incidence and prevalence rates of colorectal cancer cases across various populations. The study covers age, gender, and type as major determinants of the colorectal cancer population. The report highlights patterns in the prevalence of colorectal cancer over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on colorectal cancer epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Colorectal Cancer Understanding: Disease Overview

Colorectal cancer starts in the colon or rectum. Metastatic colorectal cancer or mCRC spreads to other organs, usually the liver, lungs, or peritoneum. It usually arises from untreated or advanced primary colorectal cancers and can spread via the bloodstream or lymphatic system. Depending on the metastatic site, symptoms may include weariness, gastrointestinal changes, weight loss, and abdominal pain. Several variables, including tumor load, genetic alterations, and general health, affect prognosis.

Colorectal Cancer Epidemiology Perspective

The colorectal cancer epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for colorectal cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for colorectal cancer and their trends. The colorectal cancer detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Colorectal cancer was responsible for 9.4% of cancer deaths and 10% of cancer incidence worldwide in 2020, and was responsible for 18% of deaths. Based on projections of aging, population expansion, and human development, it is estimated that there will be 3.2 million new cases of colorectal cancer worldwide by 2040.
• Colorectal cancer affects more than 5.25 million people globally (5-year prevalence), which is marginally less than breast cancer and accounts for 7.79 million cancer cases. The overall survival of advanced colorectal cancer (CRC) has been doubled to three years, thanks to significant efforts and advancements to better understand the disease's pathophysiology and increase treatment options. These options include endoscopic resection, surgical local excision, targeted therapy, radiation therapy, ablative therapies, chemotherapy, and immunotherapy.
• With age-standardized incidence rates of 45.3, 43.9, 41.9, 41.0, and 40.9 cases per 100,000 people, respectively, Hungary, Slovakia, Norway, the Netherlands, and Denmark have the highest incidence rates at the national level in 2020.
• With rates of 3.3, 3.7, 3.8, 3.8, and 3.8 cases per 100,000 people, respectively, Guinea, Gambia, Bangladesh, Bhutan, and Burkina Faso had the lowest age-standardized incidence rates in 2020.

Age-Based Colorectal Cancer Epidemiology Insights

After age 50, the overall incidence of CRC rises quickly. These elderly people account for 90% of cases and fatalities worldwide. Younger people, however, are more likely to develop late-stage illness. Patients under 50 years of age were more likely to present with distant illness in one SEER investigation, and colonoscopy registries have confirmed this conclusion. Unfavourable histologic subtypes and left-sided or rectal malignancies are more common in younger people.

Gender-Based Colorectal Cancer Epidemiology Insights

In 2020, the global incidence rate of colorectal cancer was 44% higher in men (23.4 cases per 100,000) than in women (16.2 cases per 100,000). Additionally, there is a bigger difference between rectal and colon cancer. Men are diagnosed with 9.8 cases of rectal cancer and 13.1 cases of colon cancer per 100,000 people, which is 75% and 31% more than the rates for women (5.6 and 10.0 cases per 100,000 people), respectively. However, worldwide cohort research conducted across ten European nations revealed that women were more likely than men to have proximal colon cancer.

Country-wise Colorectal Cancer Epidemiology Segment

The colorectal cancer epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of colorectal cancer varies between countries, owing to differences in factors such as smoking, obesity, healthcare access, and history of cancer. In the United States, the number of new cases of colorectal cancer cases are expected to grow from 0.16 million in 2020 to 0.21 million by 2040. About 20% of colorectal cancer patients in the US have distant illness when they first report, which leads to an age-adjusted rate of stage IV CRC. Another 20-30% of individuals who receive treatment for colorectal cancer with the goal of curing it experience recurring disease.

Colorectal Cancer: Treatment Overview

Systemic therapies such as chemotherapy (e.g., FOLFOX, FOLFIRI), targeted therapy (e.g., anti-EGFR or anti-VEGF drugs), and immunotherapy for certain instances with microsatellite instability (MSI-H) are commonly used in the treatment of colorectal cancer. For small metastases, especially in the liver or lungs, surgery can be a possibility. In certain situations, radiation therapy might help reduce tumors or manage symptoms. The patient's health, the degree of metastases, and the tumor's genetic makeup all influence the treatment decision.

Key Questions Answered

• What are the key findings of colorectal cancer epidemiology in the 8 major markets?
• What will be the total number of patients with colorectal cancer across the 8 major markets during the forecast period?
• What was the country-wise colorectal cancer epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of colorectal cancer patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of colorectal cancer during the forecast period of 2025-2034?
• What are the currently available treatments in the colorectal cancer market?
• What are the disease risks, signs, symptoms, and unmet needs of colorectal cancer?

Scope of the Colorectal Cancer Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of colorectal cancer based on several factors.
• Colorectal Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The colorectal cancer report helps to identify the patient population and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.